EVOTEC Aktie 505433 / DE0005664809
Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Orderbuch | Analysen | |||||
Historisch |
13.08.2025 07:00:45
|
EQS-News: Evotec SE reports H1 2025 results: Strong progress on strategy execution
EQS-News: EVOTEC SE
/ Key word(s): Half Year Report/Half Year Results
Hamburg, Germany, 13 August 2025: Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: “We are firmly on track with the execution of our strategy: Evotec is making meaningful strides toward sustainable and profitable growth. JEB maintained its strong growth trajectory with first half revenues in excess of € 100 m, and the evolution of our strategic partnership with Sandoz is testament to its bright future as a scalable technology provider with a more capital-efficient model. Our base business in D&PD continues to face soft demand, but we see strong progress in core collaborations and are systematically expanding our platform technologies, such as our Molecular Patient Database. I am confident that our unrelenting focus on technology and science leadership will continue to drive tangible impact in the future”. Discovery & Preclinical Development impacted by soft market; Just – Evotec Biologics continues strong growth momentum
Execution of strategy to refocus and deliver sustainable profitable growth fully on track
Events after Period-End
Progress in key strategic collaborations
Guidance for full-year 2025
More detailed information and financial tables are available in the half-year report published on the Evotec website under the following link: https://www.evotec.com/en/investor-relations/financial-publications
Webcast/Conference Call The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English. Date: Wednesday, 13 August 2025 Time: 2.00 pm CEST (1.00 pm BST, 8.00 am EDT) To join the audio webcast and to access the presentation slides, please register via this link. The on-demand version of the webcast will be available on our website: Financial Publications - Evotec.
Conference call details To join via phone, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call. A simultaneous slide presentation for participants dialing in via phone is available under this link.
About Evotec SE Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn. Forward-looking statements
For further information, please contact: Investor Relations Volker Braun
13.08.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
Language: | English |
Company: | Evotec SE |
Manfred Eigen Campus / Essener Bogen 7 | |
22419 Hamburg | |
Germany | |
Phone: | +49 (0)40 560 81-0 |
Fax: | +49 (0)40 560 81-222 |
E-mail: | info@evotec.com |
Internet: | www.evotec.com |
ISIN: | DE0005664809 |
WKN: | 566480 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
EQS News ID: | 2183066 |
End of News | EQS News Service |
|
2183066 13.08.2025 CET/CEST
Nachrichten zu EVOTEC SE
09:28 |
TecDAX-Handel aktuell: Börsianer lassen TecDAX zum Start steigen (finanzen.ch) | |
26.09.25 |
EVOTEC SE Aktie News: EVOTEC SE am Freitagnachmittag im Minusbereich (finanzen.ch) | |
26.09.25 |
EVOTEC SE Aktie News: EVOTEC SE am Freitagmittag Verlust reich (finanzen.ch) | |
26.09.25 |
Zurückhaltung in Frankfurt: TecDAX präsentiert sich am Mittag leichter (finanzen.ch) | |
26.09.25 |
SDAX-Handel aktuell: SDAX verbucht Verluste (finanzen.ch) | |
26.09.25 |
EVOTEC SE Aktie News: EVOTEC SE am Vormittag schwächer (finanzen.ch) | |
26.09.25 |
XETRA-Handel: SDAX zeigt sich zum Start des Freitagshandels fester (finanzen.ch) | |
24.09.25 |
Freundlicher Handel in Frankfurt: SDAX letztendlich mit grünem Vorzeichen (finanzen.ch) |
Analysen zu EVOTEC SE
03.09.25 | EVOTEC Outperform | RBC Capital Markets | |
13.08.25 | EVOTEC Buy | Warburg Research | |
13.08.25 | EVOTEC Outperform | RBC Capital Markets | |
31.07.25 | EVOTEC Hold | Deutsche Bank AG | |
30.07.25 | EVOTEC Outperform | RBC Capital Markets |
Let’s talk about Börsenjahr 2025 | Börsentag Zürich 2025
Ein besonderes Highlight des Börsentag Zürich 2025 war die grosse Diskussionsrunde mit:
👉 Thomas B. Kovacs (Sparkojote)
👉 Robert Halver (Baader Bank)
👉 Tim Schäfer (Finanzblogger, New York)
👉 Lars Erichsen (Börsencoach & YouTuber)
👉 David Kunz (COO, BX Swiss)
Gemeinsam analysieren sie die Entwicklungen an den Finanzmärkten 2025, teilen Einschätzungen zu aktuellen Trends und geben spannende Einblicke für Anleger.
📌 Themen im Fokus:
🔹Welche Krisen & geopolitischen Risiken beschäftigen die Märkte wirklich?
🔹Wie wirken sich Zölle speziell auf die Schweiz und ihre Exportwirtschaft aus?
🔹Zinspolitik: Unterschiede zwischen USA, Europa und Schweiz.
🔹Aktien vs. Immobilien: Welche Assetklasse lohnt sich 2025 mehr?
🔹Künstliche Intelligenz – Hype oder langfristiger Wachstumstreiber?
🔹Gold vs. Bitcoin: Welches Asset ist der bessere Schutz im Depot?
🔹Inflation, Liquidität und Notenbanken: Warum Sachwerte profitieren.
🔹Blick in die Glaskugel: Wo stehen Aktien & Krypto Ende 2025?
👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!
Inside Trading & Investment
Mini-Futures auf SMI
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI und DAX mit freundlichem Wochenauftakt -- Asiens Börsen mehrheitlich festerZum Start in die neue Woche verbuchen der heimische und auch der deutsche Leitindex kleine Aufschläge. An den Märkten in Fernost geht es unterdessen überwiegend nach oben.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |